Progression and Free Progression Survival Indices in Patients with Multiple Myeloma

The main feature in multiple myeloma is osteolysis and, hence, bone turnover markers have got the at mostcare different studies on this disease. present paper would stress calculation of free progressionsurvival indices using some these .Sixty-five MM (males=41, females=24) patients distributed to hematologycenters Iraq wereenrolled study. Their age range was 39-81 years, they were all three stages thediseaseaccording international staging system (ISS) : Group A – Stage I (n=21 patients, mean57.14±12.25 years), B II (n=22 mean 56.45±11.33 and C-StageIII 60.59±11.55 years). Blood samples taken from each patient just priorto starting chemotherapy for measurement blood hemoglobin (Hb), serum Creatinine, Calcium,?2 Microglubulin, Osteocalcin (OC), total Beta C-terminal telopeptide (CTX, BCTX), Parathyroidhormone (PTH), Syndecan-1 (CD138), both kappa & lambda light chain (FLC?, FLC?).There no significant association between age, sex, body weight residency with disease orprogression. From studied only CTX BCTX significantly associated thedisease progression showing varying survival times atdifferent concentrations.The comparison results newly diagnosed long-standing revealed that onlytotal FLC, FLC?, FLC? CD138 higher patients. sensitivityand specificity values among markers.